
Numinus Completes Acquisition of Neurology Centre of Toronto
Acquisition strengthens clinic portfolio for mental health treatment using psychedelic-assisted ther
Read More
Numinus to Participate in Upcoming Investor Conferences in September 2021
VANCOUVER, BC, September 2, 2021 — Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI)
Read More
Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology
VANCOUVER, BC, July 29, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a
Read More
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disor
Read More
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology
NCT’s treatment of neurological disorders combined with Numinus’ leadership in psychedelic-assis
Read More
Numinus Announces Update to Escrow Release Schedule
VANCOUVER, BC, June 25, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV:
Read More
Numinus Announces Grant of Stock Options
VANCOUVER, BC, June 24, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV:
Read More
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective a
Read More
Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
VANCOUVER, BC, June 18, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a
Read More
FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa croissance rapide et l’innovation
Des gestionnaires chevronnés pourvoient des postes de direction dans le développement des affaires
Read More
Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation
Cliquez ici pour la version française Experienced executives fill senior roles in business devel
Read More
FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement naturelle à Santé Canada en vue d’une demande d’essai pré-clinique
Le partenariat vise à offrir des capsules psychédéliques pour une étude posologique dans un ess
Read More
Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
Cliquez ici pour la version française Partnership Aimed at Delivering Psychedelic Capsule for D
Read More
FR: Numinus félicite MAPS pour son essai clinique de phase 3 révélant des bienfaits significatifs de la thérapie assistée par MDMA dans le traitement du SSPT grave
Une collaboration entre Numinus et l’Association multidisciplinaire pour les études psychédéliq
Read More
Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD
Cliquez ici pour la version française Numinus and Multidisciplinary Association for Psychedelic
Read More
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial VANC
Read More
FR: Numinus annonce un essai clinique de phase 1 sur l’extraction naturelle de champignons psilocybe préparée au laboratoire de la société
L’essai clinique évaluera la sécurité et les propriétés psychoactives de la psilocybine natur
Read More
Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab
Cliquez ici pour la version française Clinical trial will evaluate safety and psychoactive prope
Read More
Numinus Announces Listing of Warrants and Change of Trading Symbol for Previously Listed Warrants
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Van
Read More
FR: Numinus annonce la clôture d’un financement par voie de prise ferme de 40 M$
LE PRÉSENT COMMUNIQUÉ DE PRESSE EST DESTINÉ À ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT ET N’EST PAS
Read More
Numinus Announces Closing of $40-Million Bought Deal Financing
Cliquez ici pour la version française THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA O
Read More
FR: Numinus Wellness Inc. annonce un placement public de 30 M$ par voie de prise ferme
LE PRÉSENT COMMUNIQUÉ DE PRESSE EST DESTINÉ À ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT ET N'EST PAS D
Read More
Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 Million
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION T
Read More
Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering
Cliquez ici pour la version française THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA O
Read More
FR: Numinus agrandira son laboratoire de recherche ultramoderne sur les psychédéliques
Numinus Bioscience ajoutera un espace de recherche, améliorera les services contractuels, accélè
Read More
Numinus to expand state-of-the-art psychedelics research laboratory
Cliquez ici pour la version française Numinus Bioscience adds research space, enhances contract
Read More
FR: Les laboratoires Numinus au premier plan de la recherche mondiale sur les psychédéliques suite aux autorisations réglementaires
Numinus Bioscience ajoute à sa licence la kétamine et le LSD pour produire, assembler et vendre un
Read More
Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Cliquez ici pour la version française Numinus Bioscience adds Ketamine and LSD to licence to produ
Read More
FR: Numinus et Syreon fournissent une mise à jour concernant les essais cliniques à accès compassionnel sur la psilocybine
Des progrès significatifs ont été réalisés, alors que l’étude PRIME, parrainée par Numinus,
Read More
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update
Cliquez ici pour la version française Significant progress made as Numinus-sponsored PRIME study
Read More
FR: Numinus annonce des avancées dans les essais cliniques à accès compassionnel pour la thérapie assistée par MDMA en collaboration avec MAPS Public Benefit Corporation
Les essais cliniques entrent en phase préparatoire après avoir franchi plusieurs jalons importants
Read More
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation
Cliquez ici pour la version française Trial enters pre-implementation stage having met several k
Read More
FR: Numinus Wellness finalise l’acquisition de Mindspace Wellbeing, basée à Montréal
Cette acquisition renforce la présence de Numinus tout en améliorant le paysage des thérapies ass
Read More
Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing
Cliquez ici pour la version française Acquisition expands Numinus’ presence while improving ps
Read More
Numinus Engages Native Ads Inc. for Digital Media Services
VANCOUVER (February 5, 2021) – Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI),
Read More
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts
Key milestones met in ongoing trials , expanding national footprint, and enhanced research capabili
Read More
FR: Numinus Wellness fait avancer la recherche axée sur la découverte en matière de psychédéliques grâce au spectromètre de masse Orbitrap Exploris 120
L’acquisition de cet instrument de pointe de Thermo Fisher Scientific fera grandement progresser l
Read More
Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer
Cliquez ici pour la version française Acquisition of industry-leading instrument by Thermo Fishe
Read More
FR: Numinus et Optimi Health signent une entente de services de laboratoire pour faire progresser la recherche et le développement de produits psychédéliques
L’entente sera axée sur la mise au point de produits sûrs, efficaces et entièrement naturels po
Read More
Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products
Cliquez ici pour la version française The agreement will focus on developing safe, effective, al
Read More
Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Proceeds add to recently executed warrants and options of $8.9 million NOT FOR DISTRIBUTION TO UN
Read More
FR: Une clinique montréalaise offre des thérapies assistées à la kétamine
99La substance est déjà largement utilisée dans le système de santé comme anesthésique et anti
Read More
Numinus Completes First Extraction of its Psilocybe Mushrooms
Canada’s first legal extraction by a public company is a landmark moment for the global psychedeli
Read More
FR: Numinus Wellness annonce son expansion nationale avec l’acquisition de Mindspace Wellbeing, un organisme de bien-être à services complets basé à Montréal et pionnier en matière de thérapies psychédéliques
Cette association renforce la position de Numinus en tant que chef de file dans le domaine de la psy
Read More
Numinus Wellness Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming
Cliquez ici pour la version française The combination further enhances Numinus’ leadership pos
Read More
Numinus Wellness commends Health Canada for its intent to make MDMA and psilocybin treatment available through the Special Access Programme
First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in
Read More
Numinus Wellness Inc. Announces an Increase to the Previously Announced Bought Deal Public Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION T
Read More
Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED
Read More
Numinus and MAPS to Collaborate on MDMA Trial for PTSD
Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding n
Read More
“Buried by Puppies Licking Your Face” (Canadian Firms Champion MDMA for PTSD)
Numinus Wellness Inc. and Multidisciplinary Association for Psychedelic Studies Public Benefit Cor
Read More
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support
Read More
New Magic Mushroom Clinical Trial to Treat Addiction
Could magic mushrooms treat addiction? Vancouver based company Numinus has announced a new clinic
Read More
Vancouver company announces clinical trial of psilocybin-assisted psychotherapy for substance use disorders
Vancouver-based Numinus Wellness Inc. has announced a 30-person clinical trial to establish the best
Read More
Down (the Rabbit Hole) and Out (of Addiction)
Magic Mushrooms, now legal in Oregon. have shown promise in treatment of addiction and depression.
Read More
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-ass
Read More
Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms
Numinus CEO Payton Nyquvest and COO Michael Tan sat down with Forbes to discuss the company's harves
Read More
Vancouver company completes first legal harvest of psilocybe mushrooms
Vancouver-based Numinus Wellness Inc. has completed its first harvest of psilocybe mushrooms, said t
Read More
Numinus Announces First Legal Harvest of Psilocybe Mushrooms
Vancouver-based health care company Numinus Bioscience has officially harvested the first legal ba
Read More
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus Bioscience's developments include harvesting its first flush of Psilocybe mushrooms at i
Read More
Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council
Advisors, including human performance expert Jamie Wheal and mental health advocate Ben Nemtin, join
Read More
Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, acces
Read More
Numinus Announces Listing of Warrants
VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUM
Read More
Numinus Announces Closing of Oversubscribed $4.6 Million Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Van
Read More
Numinus Announces Filing of Final Short Form Prospectus for Offering of up to $4,000,000
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of
Read More
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus provides tailored treatments for clients of one of Canada's largest addiction treatment orga
Read More
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4,050,000
VANCOUVER, BC, July 28, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI
Read More
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 Million
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of
Read More
Numinus announces Clinical Advisory Council to advance integrated wellness model
Advisors including Dr. Gabor Maté and Zach Walsh bring training and expertise in psychedelic-assist
Read More
Numinus licensed by Health Canada to extract and research psilocybin
Numinus CEO, Payton Nyquvest, and Chief Operating Officer, Michael Tan, spoke to Mugglehead about an
Read More
Numinus Licencing Amendment: We Speak to the Team
Numinus Chief Operating Officer Michael Tan explains what the company's recent Health Canada licence
Read More
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes first publicly traded company in Canada approved to conduct research of this kind u
Read More
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Medical doctor experienced in psychedelic assisted therapy and research to help advance Numinus
Read More
Numinus Announces 2020 Operational Plans to Scale
Company gives guidance on near-term business objectives VANCOUVER (May 28th, 2020)— Numinus Wel
Read More
Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections wi
Read More
Canada could regulate psychedelic therapy within few years, bets company
Numinus Wellness outlines where they see the business and the industry going following their public
Read More
Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer
Wood will lead research partnerships and the design of the Numinus patient-focused mod
Read More
Numinus Wellness Inc. commences trading on TSX Venture Exchange as NUMI
Integrated company to play a lead role in emerging psychedelic assisted therapy and research space
Read More
Numinus Wellness Inc. (formerly Rojo Resources Ltd.) closes RTO with Salvation Botanicals LTD; to commence trading under “NUMI”
Numinus Wellness Inc. (formerly Rojo Resources Ltd., RJ:H) (“Numinus” or the “Company”) (TSX
Read More
Rojo Resources Ltd. announces the conditional approval of reverse take-over transaction with Salvation Botanicals Ltd.
Rojo Resources Ltd. (“Rojo” or the “Company”) (TSXV: RJ:H) is pleased to announce that it ha
Read More
Rojo Resources Ltd. announces closing of subscription receipt offering, Salvation Botanicals closes sidecar private placement – aggregate gross proceeds of $6,000,000 raised
VANCOUVER (March 10, 2020) — Rojo Resources Ltd. (“Rojo” or the “Company”) (TSXV: RJ:H) is
Read More
End-to-end solution in psychedelic therapies establishes Numinus as leader in emerging space
VANCOUVER (February 24, 2020)—With momentum building for the use of psychedelic substances in the
Read More